Semaglutide helps reduce risk of heart attack, stroke in people without diabetes, study finds - ABC News

Semaglutide is the main ingredient in Wegovy and Ozempic. A recent study found it may help reduce the risk of heart attack and stroke in people without diabetes.
Semaglutide is the main ingredient in medications including Wegovy and Ozempic.
ABC News’ Dr. Jennifer Ashton explains a new study in the New England Journal of Medicine that shows a reduction in heart attacks, strokes and death in overweight or obese participants who took semaglutide.

Wegovy Slashes the Risk of Heart Attack and Stroke in a Landmark Trial

Wegovy study: Semaglutide reduced risks for heart attacks, strokes - UCHealth Today

Weight-loss drug Wegovy cuts heart attack, stroke risk by 20%, study says

Popular weight loss drug Wegovy also found to lower the risk of heart attacks, strokes - ABC News

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial, Cardiovascular Diabetology

Trial confirms heart benefits of Wegovy, but is weight loss responsible – or something else?, Health

Danielle Belardo, M.D. on Instagram: HUGE NEWS! Contrary to popular belief: GLP-1 weight loss medications are NOT all about aesthetics, they REDUCE risk of cardiovascular death, heart attack, stroke, heart failure, AND

Semaglutide helps reduce risk of heart attack, stroke in people without diabetes, study finds - ABC News

Discovering added benefits from some medications

SELECT trial shows cardiovascular risk reduction in non-diabetics taking semaglutide - Cardiac Rhythm News

Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention

Remote Health Solutions

Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association

Newer drug may be an alternative to help lower heart disease risk, study finds - Everett Post

Remote Health Solutions